© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Merestinib stands as a small-molecule kinase inhibitor, mainly researched in cancer therapies. It interrupts multiple receptor tyrosine kinases, including MET, AXL, and RON. Every chemist or lab technician who encounters this substance starts with its raw appearance: a solid material, typically found as an off-white to light yellow crystalline powder. The structure of Merestinib features a complex arrangement of aromatic rings and a sulfonamide group, contributing to its selectivity and specificity. Knowledge of its makeup and properties helps anyone working with Merestinib handle it properly, store it in the right conditions, and use it in research or applications designed to leverage its molecular activity.
Merestinib’s molecular formula is C28H33FN4O3S, reflecting the presence of fluorine, nitrogen, oxygen, and sulfur. It brings a molecular weight of around 524.65 g/mol. The compound’s solid state expresses itself in crystals or fine powder, a detail which determines how it looks and how people handle it. The crystal system architecture not only affects how it dissolves but influences milling, mixing, and solution preparation in laboratory and industrial settings. Laying eyes on the substance in a chemistry lab, one recognizes the granular, sometimes flaky or pearled solid. It doesn’t appear as a clear liquid; its density stays stable in its solid state, measured at approximately 1.34 g/cm³ at room temperature. As someone who has sorted through many chemical cabinets, those numbers mean something: they point to how Merestinib packs, ships, and pours out onto a balance or into a beaker.
Handling Merestinib means respecting its unique combination of material properties. The substance melts at temperatures above 220°C, and this high melting point tells technicians that standard storage conditions do not bring risk of phase transition. This isn’t a granular compound that dissolves in every solvent but requires choice solvents, such as dimethyl sulfoxide (DMSO) or methanol, for proper solution preparation. Water solubility is weak, so those working in pharmaceutical or lab environments need to plan around its limited dispersion in aqueous solutions. Its property as a solid—usually powder, but occasionally forming pearl- or flake-like crystals—demands dry, tightly sealed storage. Experience with laboratory chemicals teaches that moisture or air can ruin samples if left exposed, degrading product quality and reliability.
Merestinib typically moves through international trade under HS code 2934999099, which covers organic compounds that fall outside more specific categories. Recognizing this code proves critical for importers and customs officials. Laboratories and chemical distributors keep compliance at the forefront; missing the right code can mean unnecessary inspection, delay, or even regulatory penalty. Whether someone is shipping as a manufacturer, researcher, or pharma company, clear labeling and correct paperwork speed up delivery and uphold legal standards. Seeing so many supply chain hiccups in the past shows that proper HS code application cuts down headaches across borders.
Merestinib qualifies as hazardous and harmful in some settings. Professional wisdom says never skimp on protective equipment: gloves, goggles, and proper lab attire set the norm. Exposure risks include irritation of skin, eyes, or the respiratory system, and anyone who remembers a chemical burn or allergic reaction knows how important caution becomes. Material safety data sheets indicate Merestinib’s R-phrases and S-phrases, stressing the importance of spill management and specific disposal methods. Waste containing Merestinib can’t be treated like everyday trash—instead, incineration in approved facilities ensures breakdown and neutralization. From decades of collective lab work, the lessons in chemical stewardship ring true: careless handling increases health and environmental risks, while careful control pays off in personal safety and environmental protection.
Merestinib starts with complex organic synthesis, involving raw materials like aromatic hydrocarbons, fluorinated precursors, and specialty sulfonamides. These base materials come from high-purity processes because product integrity matters for advanced applications like cancer therapy research. I have seen firsthand how variability in raw material supply can slow or even halt research projects. Inconsistent input quality leads to varying results in compound purity, making batch records, supplier audits, and analytical confirmation essential in pharma manufacturing. A steady, audited supply of raw ingredients makes or breaks development and production timelines, so companies build their procurement and testing routines accordingly.
Merestinib’s main role sits in research and development of oncology drugs aimed at inhibiting key drivers of tumor growth and metastasis. Its targeted activity makes it valuable in preclinical studies, animal trials, and sometimes experimental drug therapy programs. As research continues, scientists keep pushing for new compounds with improved efficacy, fewer side effects, and lower toxicity. Key development goals move toward green chemistry and sustainable production. Reducing hazardous waste, recycling solvents, and designing safer synthesis pathways lock in benefits for both people and planet. By sharing experiences in labs, exchanging best practices, and adapting international regulatory frameworks, industry stakeholders can lower risks and strengthen confidence in Merestinib’s future uses.
